A Japanese health ministry panel on Wednesday delayed emergency approval for an oral treatment against COVID-19 that has been developed by Shionogi & Co.
Less than a month after a hard-won deal was reached on a partial waiver of intellectual property rights for COVID-19 vaccines, a fresh battle may be looming at the World Trade Organization over extending the waiver to treatments and tests.
The U.S. Food and Drug Administration said on Wednesday it had authorized state-licensed pharmacists to prescribe Pfizer Inc’s (PFE.N) COVID-19 pill to eligible patients to help improve access to the treatment.
People in socially and economically disadvantaged regions are about half as likely to receive an oral antiviral COVID-19 pill than residents of wealthier zip codes, according to a U.S. government study published on Tuesday.
FDA, HHS sued by doctors over controversial drug ivermectin Published: Jun 21, 2022 By Mark Terry BioSpace Earlier this month, three physicians filed a lawsuit against the Department of Health and Human Services (HHS), HHS Secretary Xavier Becerra, the U.S. Food and Drug Administration, and FDA Commissioner Robert M. Califf in a Texas court. They […]
Pfizer Inc. said on Tuesday the company would halt enrollment in a trial for its COVID-19 antiviral drug, Paxlovid, in standard-risk patients after a study revealed the treatment was not effective in reducing symptoms in that group.
AstraZeneca announced Wednesday that the results of the company’s TACKLE Phase III trial of Evusheld (tixagevimab and cilgavimab, formerly AZD7442) for the early outpatient treatment of mild-to-moderate COVID-19 have been published in The Lancet Respiratory Medicine. Results of the trial showed that Evusheld protected against progression to severe COVID-19 or death – from any cause – compared to placebo.
Use of Pfizer Inc.’s COVID-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a U.S. public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time.
Patients who experience recurrence of COVID-19 symptoms after completing treatment with Pfizer’s drug Paxlovid should isolate again for five days, the U.S. Centers for Disease Control and Prevention said in an advisory issued on Tuesday.